natgillin/translations-raw huggingface dataset:
This is of particular importance because Coxiella burnetii can lead to a disease in humans called Q- fever and decreasing the disease in animals will decrease the likelihood of transmitting the disease to humans.
Ovo je od posebne važnosti budući da bakterija Coxiella burnetii može rezultirati bolešću u ljudi naziva Q-groznica, te smanjivanjem bolesti u životinja smanjuju se izgledi za prijenos ove bolesti na ljude.
This is one 2.5 mg tablet once a day.
Ta je doza jedna tableta od 2,5 mg jedanput na dan.
This is part of a multipack of 10 pens and not for sale as individual pens
Ovo je dio višestrukog pakiranja od 10 brizgalica i nije predviđeno za pojedinačnu prodaju brizgalica.
This is particularly important if you are already taking any medicine to treat a heart condition or problems with your blood sugar, kidneys or blood pressure such as medicines containing
To je naročito važno ako već uzimate neki lijek za liječenje srca ili problema sa šećerom u krvi, bubrezima ili krvnim tlakom, kao što su lijekovi koji sadrže
This is particularly important if you are taking any of the following as your doctor may need to adjust your dose of Emselex and/or the other product:
To je posebno važno ako uzimate bilo koji od sljedećih lijekova, jer će Vaš liječnik možda morati prilagoditi dozu Emselexa i/ili drugog lijeka:
This is particularly important if you are taking the following medicines which may interact with Fortacin:
To je osobito važno ako uzimate sljedeće lijekove koji mogu reagirati s Fortacin:
This is particularly important in children under the age of 2 years (see ‘Do not use Mirvaso’).
To je posebno važno za djecu mlađu od 2 godine (pogledajte “Nemojte primjenjivati Mirvaso“).
This is particularly important:
To je osobito važno:
This is particularly significant if these are accompanied by either of the following symptoms:
Navedeno je od posebnog značaja ako je praćeno bilo kojim od sljedećih simptoma:
This is particularly suitable if:
To je osobito pogodno:
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves.
To je dijelom povezano s poboljšanim zdravljem i stilom života, dok je u slučaju masnoća u krvi katkad povezano i s lijekovima za liječenje HIV-a.
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves.
To je djelomično povezano s poboljšanim zdravljem i načinom ţivota, dok je u slučaju lipida u krvi katkad povezano i sa samim lijekovima za liječenje HIV-a.
This is recommended to be performed every 6 months.
Ovakva se kontrola preporuča svakih 6 mjeseci.
This is regarded as a significant improvement in the diagnosis of patients with memory problems who are being evaluated for Alzheimer’s disease and other types of dementia.
Ovo se smatra značajnim poboljšanjem u dijagnozi bolesnika s problemima u pamćenju koje testira na Alzheimerovu bolest i druge demencije.
This is seen in the following table:
To je vidljivo u sljedećoj tablici:
This is seen on an electrocardiogram (ECG).
To se vidi na elektrokardiogramu (EKG-u).
This is shown in Picture 3 at the beginning of these instructions.
To je prikazano na slici 3 koja se nalazi na početku uputa za primjenu.
This is shown in the diagram.
To je prikazano na slici.
This is similar to a response rate of 78% observed in patients with wild-type RAS given Vectibix with FOLFOX.
Ovo je slično stopi odgovora na liječenje od 78 % u bolesnika s divljim tipom gena RAS koji su primali lijek Vectibix u kombinaciji s „FOLFOX” kemoterapijskim protokolom.
This is so that you can measure the dose correctly.
Svrha je toga da možete pravilno izmjeriti dozu.
This is so that you can measure the dose correctly.
Svrha je toga da pravilno izmjerite dozu.
This is so that you can measure the dose correctly.
To je zato da možete pravilno izmjeriti dozu.
This is so your doctor can: decide if you should take ZEPATIER and for how long decide what other medicines you should take with ZEPATIER and for how long
Na taj način Vaš liječnik može: odlučiti trebate li uzimati ZEPATIER i koliko dugo odlučiti koje druge lijekove trebate uzimati s lijekom ZEPATIER i koliko dugo
This is sometimes called insulin-dependent diabetes
ako imate šećernu bolest tipa 1 koja se ponekad naziva šećernom bolešću ovisnom o inzulinu.
This is suitable for younger children and babies: they usually need a Tamiflu dose of less than 30 mg.
potrebna doza lijeka Tamiflu manja od 30 m
This is suitable for younger children and babies: they usually need a Tamiflu dose of less than 30 mg.
To je obično primjereno za mlađu djecu i dojenčad: njima je obično potrebna doza lijeka Tamiflu manja od 30 mg.
This is suitable for younger children and babies: they usually need an Ebilfumin dose of less than 30 mg.
To je obično primjereno za mlađu djecu i dojenčad: njima je obično potrebna doza lijeka Ebilfumin manja od 30 mg.
This is suitable for younger, lighter children and babies: they usually need a Tamiflu dose of less than 45 mg.
To je obično primjereno za mlađu djecu i dojenčad: njima je obično potrebna doza lijeka Tamiflu manja od 45 mg.
This is suitable for younger, lighter children and babies: they usually need an Ebilfumin dose of less than 45 mg.
To je obično primjereno za mlađu, lakšu djecu i dojenčad: njima je obično potrebna doza lijeka Ebilfumin manja od 45 mg.
This is supported by 96 week data from an open-label, randomized and active- controlled study FLAMINGO (ING114915) and additional data from the open-label phase of SINGLE to 144 weeks.
Podupiru ih i podaci prikupljeni tijekom96 tjedana u otvorenom, randomiziranom i aktivno kontroliranom ispitivanju FLAMINGO (ING114915) i dodatni podaci iz otvorene faze ispitivanja SINGLE do 144. tjedna.
This is the approximate number of doses that can be delivered from the nasal spray, before the battery is too low and the display turns off.
To je približan broj doza koji se može isporučiti iz spreja za nos prije nego što baterija postane preslaba, a zaslon se isključi.
This is the most common appearance of a positive scan;
Pozitivna snimka najčešće je takvoga izgleda;
This is the number of injection sites and the total number of syringes (each filled with 0.5ml) needed to administer a volume of 0.5ml per injection site for the patient’s treatment.
Tako dobijete broj mjesta injiciranja i ukupan broj potrebnih štrcaljki (svaka napunjena sa 0,5 ml) potrebnih za primjenu volumena od 0,5ml po mjestu injiciranja za liječenje bolesnika.
This is the number of injection sites and the total number of syringes (each filled with 0.5ml) required for the patient’s treatment.
Tako se dobije broj mjesta injiciranja i ukupan broj potrebnih štrcaljki (svaka napunjena sa 0,5 ml) za liječenje bolesnika.
This is the number of vials that must be dispensed.
Tako dobijete broj bočica koje treba primijeniti.
This is then followed by a second phase in which 3 mg/kg nivolumab is administered as an intravenous infusion over 60 minutes every 2 weeks.
Nakon toga slijedi druga faza, u kojoj se nivolumab u dozi od 3 mg/kg primjenjuje kao intravenska infuzija u tijekom 60 minuta svaka 2 tjedna.
This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction).
Nakon toga slijedi standardna doza od 75 mg jednom na dan tijekom najmanje četiri tjedna (u slučaju infarkta miokarda "povišenja ST segmenta") ili do 12 mjeseci (u slučaju nestabilne angine ili "non-Q" infarkta miokarda).
This is thought to be due to activation of feedback mechanisms without adverse clinical consequence.
To se pripisuje aktivaciji mehanizma povratne sprege, bez štetnih kliničkih posljedica.
This is thought to lead to increases in the levels of dopamine and noradrenaline between nerve cells in the areas of the brain that are involved in the control of mood.
Smatra se da ovo uzrokuje povišenje razina dopamina i noradrenalina između živčanih stanica u područjima mozga koja su uključena u kontrolu raspoloženja.
This is to account for intravenous infusion line loss and to assure that the patient will receive the full dose of BLINCYTO.
Razlog za to je da se nadoknadi gubitak u cjevčici za intravensku infuziju te da se osigura primjena pune doze lijeka BLINCYTO u bolesnika.
This is to be expected as the therapeutic principle of photodynamic therapy is based on phototoxic effects of protoporphyrin IX which is synthesized from the active ingredient 5- aminolaevulinic acid.
To je očekivano, jer se terapijsko načelo liječenja fotodinamskom terapijom zasniva na fototoksičnim učincima protoporpfirina IX koji se sintetizira iz djelatne tvari 5- aminolevulinatne kiseline.
This is to check how well your liver and your kidneys are working.
To se čini da bi se provjerilo koliko dobro rade Vaša jetra i bubrezi.
This is to check how well your liver is working.
Time će provjeriti koliko dobro radi Vaša jetra.
This is to help limit flu-like symptoms.
To može pomoći u ograničavanju simptoma poput gripe.
This is to hide the bitter taste of the Tamiflu powder.
Dobro promiješajte mješavinu.
This is to prevent your symptoms from coming back again or becoming worse.
To se radi kako bi se sprječilo da se simptomi ponovo pojave ili da postanu teži.
This is to reduce the risk of injection site reactions.
Time se smanjuje rizik od reakcija na mjestu davanja injekcije.
This is translated into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation.
To se prenosi na odgodu vremena latencije ejakulacije bez narušavanja osjećaja ejakulacije.
This is uncommon (affects less than 1% of the women).
To je manje često (javlja se u manje od 1% žena).
This is unlikely to happen again.
Mala je vjerojatnost da se to dogodi ponovno.
This is used in exactly the same way.Use of purple
Ona se upotrebljava na posve isti način.
This is usually given every 3 weeks up to 8 times.
Ona se obično primjenjuje svaka 3 tjedna, najviše 8 puta.
This is usually reversible if 6–mercaptopurine therapy is stopped soon enough but fatal liver damage has occurred.
Ona je obično reverzibilna ako se liječenje 6-merkaptopurinom prekine dovoljno rano, ali su zabilježeni i slučajevi smrtonosnog oštećenja funkcije jetre.
This is very common (may affect more than 1 in 10 people).
To je vrlo česta nuspojava (može se javiti u više od 1 na 10 osoba).
This is very common in severe chronic neutropenia patients, common in HIV patients and uncommon in normal stem cell donors. if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria).
To je vrlo često u bolesnika s teškom kroničnom neutropenijom, često u bolesnika s HIV infekcijom i manje često u zdravih darivatelja matičnih stanica. ako se liječite zbog teške kronične neutropenije i imate krv u mokraći (hematurija).
This is very common in severe chronic neutropenia patients, common in HIV patients and uncommon in normal stem cell donors. if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria).
To je vrlo često u bolesnika s teškom kroničnom neutropenijom, često u bolesnika s HIV infekcijom i manje često u zdravih darivatelja matičnih stanica. ako se liječite zbog teške kronične neutropenije i imate krv u mokraći (hematuriju).
This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time.
To je vrlo vaţno zato što količina virusa moţe početi rasti ako se čak i nakratko prestane uzimati lijek.
This is what causes the symptoms of MS.
To uzrokuje simptome MS-e.
This is what the vial should now look like.
Bočica sada treba izgledati ovako.
This is when you and your doctor agree that the symptoms are adequately controlled and the side effects of the medicines are acceptable.
To se događa kad zaključite sa svojim liječnikom da su simptomi odgovarajuće kontrolirani i da su nuspojave lijekova prihvatljive.
This is when your bones are more likely to break.
To je stanje kad Vam se kosti lakše lome.
This is where you have contractions of your neck or shoulder muscles that you cannot control.
To je kada imate stezanja (kontrakcije) mišića vrata ili ramena koja ne možete kontrolirati.
This is why the vaccine suspension should only be prepared as and when required.
Zato suspenziju cjepiva treba pripremiti kako i kada je potrebna.
This is why your child will be kept under close clinical and heart rate monitoring for 2 hours after the first dose or after a dose increase.
Zbog toga će vaše dijete biti pod strogim kliničkim nadzorom i praćenjem otkucaja srca tijekom 2 sata nakon primjene prve doze ili nakon povećanja doze.
This Ki value is far higher than the expected plasma levels of imatinib in patients, consequently no interaction is expected upon co- administration of either 5-fluorouracil or paclitaxel and imatinib.
Ta Ki vrijednost je daleko viša nego što su očekivane razine imatiniba u plazmi bolesnika, pa se prema tome ne očekuje nikakva interakcija nakon istodobne primjene bilo 5-fluorouracila bilo paklitaksela i imatiniba.
This kills the cells by reacting with and destroying their components, such as proteins and DNA.
Stanice se uništavaju reaktivnim djelovanjem u stanicama i uništavanjem njihovih sastavnica, kao što su proteini i DNK.
This lack of oestrogen leads to a thinning of the tissues in and around the vagina and a reduction in the amount of mucus that keeps the vaginal environment moist.
Taj manjak estrogena rezultira stanjivanjem tkiva unutar i oko vagine, te smanjenjem količine sluzokože
This last triple pack should be used for treatment days 19, 21 and 23.
Posljednje trostruko pakiranje treba upotrijebiti za dane liječenja 19, 21 i 23.
This le afle t was last approve d in
Uputa je zadnji puta odobre na u {MM/GGGG}.
This le afle t was last approved in
Uputa je zadnji puta odobre na u {MM/GGGG}.
This leads to a reduction in the release of substances that are involved in the inflammation process, such as histamine, thereby helping to keep the airways clear and allowing the patient to breathe more easily.
Ovo rezultira smanjenjem u otpuštanju tvari koje su uključene u upalni proces, poput histamina, te tako pomaže pri održavanju zračnih putova čistima i omogućuje bolesnicima olakšano disanje.
This leads to an increased production of platelets.
Na taj se način povećava stvaranje trombocita.
This leads to changes in the activity of the brain, bringing about ‘delta’ (slow) brain waves and night-time sleep.
To uzrokuje promjene u aktivnosti mozga, aktivira „delta” (spore) valove u mozgu i dovodi do noćnog sna.
This leads to high blood pressure in the vessels taking blood from the heart to the lungs and reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.
To dovodi do visokog krvnog tlaka u žilama koje krv odvode iz srca u pluća te smanjuje količinu kisika koji može doprijeti u krv u plućima, što otežava fizička aktivnost.
This leads to high levels of glucose in the blood.
Ovo rezultira visokim razinama glukoze u krvi.
This leads to high levels of glucose in the blood.
To rezultira visokom koncentracijom glukoze u krvi.
This leads to inflammation in many parts of the body, with symptoms such as fever, rash, joint pain and tiredness.
To uzrokuje upalu u mnogim dijelovima tijela sa simptomima poput groznice, osipa, boli u zglobovima i umora.
This leads to inhibition of cell growth, while showing significantly less activity against EGFR in wild- type cell lines (apparent IC50s from 480 nM to 1.8 μM against phospho-EGFR).
To dovodi do inhibicije rasta stanica, istodobno pokazujući značajno manje aktivnosti spram EGFR-a u staničnim linijama divljeg tipa (utvrđene vrijednosti IC50 od 480 nM do 1,8 µM za fosfo-EGFR).
This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease.
Ovo rezultira manjim gubitkom kostiju u osteoporozi i smanjenom aktivnošću Pagetove bolesti.
This leads to less bone loss in osteoporosis and less disease activity in Paget’s disease.
Ovo uzrokuje manji gubitak kosti u slučaju osteoporoze i manju aktivnost bolesti u slučaju Pagetove bolesti.
This leads to less bone loss.
Ovo rezultira snižavanjem gubitka kosti.
This leads to less disease activity in Paget’s disease.
Ovo uzrokuje smanjenje aktivnosti bolesti u slučaju Pagetove bolesti.
This leads to phosphate accumulating in the body, which, in the long term, can cause complications such as heart disease.
Ovo rezultira nakupljanjem fosfata u tijelu, što dugoročno, može uzrokovati komplikacije poput srčane bolesti.
This leaflet has been written as though the person taking the medicine is reading it.
Ova je uputa pisana kao da je čita osoba koja uzima lijek.
This leaflet is available in all EU/EEA languages on the European Medicines Agency web site.
Ova Uputa o lijeku je dostupna na svim EU/EEA jezicima na web stranicama Europske agencije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website
Ova Uputa o lijeku je dostupna na svim EU/EEA jezicima na web stranicama Europske agencije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Ova je uputa dostupna na svim EU/EEA jezicima na web stranicama Europske agencije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Ova uputa je dostupna na svim EU/EEA jezicima na web stranici Europske agencije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Ova uputa je dostupna na svim EU/EEA jezicima na web-mjestu Europske komisije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Ova uputa je dostupna na svim jezicima zemalja Europske Unije/Europskog gospodarskog prostora na web stranici Europske Agencije za lijekove.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
Ova Uputa o lijeku dostupna je na svim EU/EEA jezicima na web stranicama Europske agencije za lijekove.
This leaflet is available in formats suitable for the blind or partially sighted patient and can be requested from respective local representative of the Marketing Authorisation Holder.
Ova je uputa dostupna u formatima za slijepe i slabovidne osobe a može se zatražiti od lokalnog predstavnika nositelja odobrenja za stavljanje gotovog lijeka u promet.
This leaflet was approved in
Ova uputa je zadnji puta odobrena u.
This leaflet was approved in Other sources of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last approved
Uputa je zadnji put odobrena
This leaflet was last approved in
Ova uputa je zadnji put odobrena
This leaflet was last approved in
Ova uputa je zadnji put revidirana u
This leaflet was last approved in
Uputa je zadnji put odobrena u
This leaflet was last approved in .
Ova uputa je zadnji puta odobrena u .
This leaflet was last approved in .
Ova uputa je zadnji puta revidirana u
This leaflet was last approved in .
Uputa je zadnji puta odobrena u
This leaflet was last approved in MM/YYYY.
Ova uputa je zadnji puta revidirana u MM/GGGG
This leaflet was last approved in MM/YYYY.
Uputa je zadnji puta odobrena u MM/GGGG.
This leaflet was last approved in Other sources of information
E-mail: info@biopartners.de Uputa je zadnji puta odobrena u Drugi izvori informacija
This leaflet was last approved in Other sources of information
Ova uputa je zadnji puta odobrena u Drugi izvori informacija
This leaflet was last approved in {MM/YYYY}
Ova je uputa zadnji puta odobrena u {MM/GGGG}
This leaflet was last approved in {MM/YYYY}
Ova uputa je zadnji put revidirana u {MM/GGGG}
This leaflet was last approved in {MM/YYYY}
Ova uputa je zadnji puta odobrena u {MM/GGGG}
This leaflet was last approved in {MM/YYYY}
Ova uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last approved in {MM/YYYY}
Ova uputa je zadnji puta revidirana u {MM/GGGG}.
This leaflet was last approved in {MM/YYYY}
Ova uputa o lijeku je zadnji put odobrena u {MM/GGGG}
This leaflet was last approved in {MM/YYYY}
Uputa je zadnji puta odobrena u {MM/GGGG}.
This leaflet was last approved in {MM/YYYY}.
Ova uputa je zadnji puta revidirana u <mjesec GGGG>.
This leaflet was last approved in {MM/YYYY}.
Ova uputa je zadnji puta revidirana u {mjesec/GGGG}.
This leaflet was last approved in {MM/YYYY}.
Uputa je zadnji puta odobrena u {MM/ GGGG}.
This leaflet was last approved in {MM/YYYY}.
Uputa je zadnji puta odobrena u {MM/GGGG}
This leaflet was last approved in:
Uputa je zadnji put odobrena u:
This leaflet was last approved on
Ova uputa je zadnji puta odobrena u
This leaflet was last approved on XXXXX
Uputa je zadnji puta odobrena XXXXX
This leaflet was last last revised in <{MM/YYYY}> <{month YYYY}>
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}.>
This leaflet was last revised in
Ova je uputa je zadnji put revidirana u
This leaflet was last revised in
Ova Uputa je posljednji puta revidirana
This leaflet was last revised in
Ova uputa je zadnji puta revidirana u: 05/2016
This leaflet was last revised in (MM/YYYY).
Ova uputa je zadnji puta revidirana u (MM/GGGG)
This leaflet was last revised in (MM/YYYY).
Ova uputa je zadnji puta revidirana u {MM/GGGG}.
This leaflet was last revised in .{MM/YYYY}.
Ova uputa je zadnji puta revidirana u {MM/GGGG}.
This leaflet was last revised in <MM/YYYY>
Ova uputa je zadnji puta revidirana u <MM/GGGG>.
This leaflet was last revised in <month YYYY>
Ova uputa je zadnji puta revidirana u <mjesec GGGG>
This leaflet was last revised in <Month YYYY>
Ova uputa je zadnji puta revidirana u <mjesec GGGG>.
This leaflet was last revised in <{MM/YYYY}
Uputa je zadnji put odobrena <{MM/GGGG}
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}
Uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Ova uputa je zadnji puta revidirana u
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.>
Ova uputa je zadnji puta revidirana u <{MM/GGGG}><{mjesec GGGG}.>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.> Other sources of information
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}.> Drugi izvori informacija
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}.>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}>
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.
Ova je Uputa zadnji put revidirana <{MM/GGGG}> <{mjesec GGGG}>.
This leaflet was last revised in <{MM/YYYY}> Other sources of information
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> Drugi izvori informacija
This leaflet was last revised in <{MM/YYYY}> Other sources of information
Ova uputa je zadnji puta revidirana u <{MM/YYYY}> Ostali izvori informacija
This leaflet was last revised in <{MM/YYYY}><{month YYYY}.>
Uputa je zadnji puta revidirana u <{MM/GGGG}><{mjesec GGGG}.>
This leaflet was last revised in <{MM/YYYY}><{month YYYY}>
Ova uputa je zadnji puta revidirana u <{MM/GGGG}> <{mjesec GGGG}>
This leaflet was last revised in <{month YYYY}>.
Ova uputa je zadnji puta revidirana u <{mjesec GGGG}.>
This leaflet was last revised in April/2014
Ova uputa je zadnji puta revidirana u <{MM/GGGG}>
This leaflet was last revised in MM/YYYY
Uputa je zadnji puta revidirana u MM/ GGGG
This leaflet was last revised in MM/YYYY Other sources of information
Ova uputa je zadnji puta revidirana u MM/GGGG Drugi izvori informacija
This leaflet was last revised in MM/YYYY Other sourses of information
Ova uputa je zadnji puta revidirana u MM/GGGG Drugi izvori informacija
This leaflet was last revised in MM/YYYY.
Ova uputa je zadnji puta revidirana u MM/GGGG
This leaflet was last revised in MM/YYYY}
Ova uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last revised in Month YYYY Other sources of information
Ova uputa je zadnji puta revidirana u mjesec GGGG Ostali izvori informacija
This leaflet was last revised in month YYYY.
Ova uputa je zadnji puta revidirana u